Dear Sir/Madam,

National Stock Exchange of India Limited,	**BSE Limited,**
Compliance Department,	Compliance Department,
Exchange Plaza, Bandra Kurla Complex,	Phiroze Jeejeebhoy Towers,
Bandra (East), Mumbai - 400051,	Dalal Street, Mumbai - 400001,
Maharashtra, India	Maharashtra, India

Subject : ***Investor Presentation on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026***

Stock Code : ***BSE – 539787, NSE – HCG***

Reference : ***Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015***

This is to inform you that the Board of Directors of the Company, at their meeting held today i.e. August 06, 2026, inter alia, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026 ("Financial Results").

We enclose herewith the Investor Presentation on the Financial Results of the Company.

The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/investor-relations/

You are requested to take the information on record.

Thanking you,
For **HealthCare Global Enterprises Limited**

SUNU MANUEL ABEY

Digitally signed by SUNU MANUEL ABEY
Date: 2026.08.06 20:36:11 +05'30'

Sunu Manuel
Company Secretary & Compliance Officer
Encl:a/a

HEALTHCARE GLOBAL ENTERPRISES LIMITED

Q1 FY2027 Results Presentation

August 6, 2026

Safe Harbor

This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by **HealthCare Global Enterprises Limited (the "Company")**. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.

Strategic Progress Over the Past Year

Executing Our Strategy | Building the Foundation for Sustainable Long-Term Value Creation

Focus on core oncology

Completed Strategic Exit from Milann

- ✓ Sharpened focus on core-oncology
- ✓ Enhanced management focus and execution
- ✓ Strengthening clinical differentiation

Capacity expansion

North Bengaluru Hospital Operational

- ✓ 120+ beds capacity added in May 26
- ✓ State-of-the-art MR-LINAC commissioned
- ✓ Strengthens leadership in Bengaluru market

Capital strength

Successfully Completed Rights Issue

- ✓ Strengthened Balance sheet
- ✓ Enhanced financial flexibility
- ✓ Well positioned to fund future growth

Leadership

Management Team Strengthened

- ✓ Leadership team fully on-boarded
- ✓ Execution capability strengthened
- ✓ Enhanced institutional governance

Growth pipeline visibility

Bed Expansion Progressing

- ✓ Brownfield expansion in high potential centers
- ✓ Unlocking embedded capacity across network
- ✓ Return focused capital investment

Operational excellence

Key Initiatives Underway

- ✓ Cost optimization
- ✓ Driving productivity improvements
- ✓ Enhancing patient experience

Q1 FY27: Performance Update

adding life to years

Revenue grew 13% y-o-y, while Adjusted EBITDA grew 20% y-o-y, with margins improving to 19.4% compared to 18.2% in Q1 FY26

Financial Highlights

			Margins
Revenue	6,951 Mn	13% y-o-y	
Reported EBITDA	1,223 Mn	13% y-o-y	17.6%
Adjusted EBITDA[1]	1,339 Mn	20% y-o-y	19.4%
Profit after Tax[2]	138 Mn	190% y-o-y	2.0%

Operational Highlights

Volume	78,914	11% y-o-y
ARPP	85,943	2% y-o-y
Non-Institutional Mix	69%	189 bps y-o-y
Operational Beds	2,855	121 Beds Addition QoQ

Notes:
1. Adjusted EBITDA excludes North Bangalore Loss of INR 70 Mn and EPCG-related provision of INR 45.9 Mn in Q1 FY27 and ESOP of INR 14.5 Mn and M&A-related costs of INR 25.6 Mn in Q1 FY26
2. Profit after Tax is profit attributable to the owners of the company

HCG Key Highlights: Q1 FY27

adding life to years

HCG delivered revenue of INR 6,951 Mn in Q1FY27, reflecting ~13% YoY growth

- Broad-based growth continued across clusters in Q1FY27. Revenue growth was led by volume growth of 11% y-o-y. ARPP grew by 2%, improvement driven by a favourable payor mix was partly offset by changes in case mix, including a lower contribution from high-value, low-margin therapies
  - **South** Revenue of INR 2,765 Mn (contributing 40% of revenue) delivered ~16% YoY growth
    - Balanced growth from volume and realization. Bangalore CoE and MGCH in AP region witnessed improvement in Cash + TPA mix
  - **West** Revenue of INR 3,010 Mn (contributing 43% of revenue) delivered ~9% YoY growth.
    - Strong revenue growth in Maharashtra region was offset by moderated growth in Gujarat region
    - Led by increase in patient volumes (10% YoY growth). ARPP was impacted due to higher share of medical oncology and rationalization of high-value, low-margin therapies
  - **East** Revenue of INR 799 Mn (contributing 11% of revenue) grew ~22% YoY
    - Higher patient volumes (25% YoY growth). ARPP declined 3% YoY due to case-mix changes and a higher contribution from state-government schemes
- International business revenue was INR 208 Mn, grew ~9% YoY in Q1FY27, driven by stronger patient inflows for radiation oncology and PET cases
- Fertility Business divested in June 26; delivered revenue of INR 169 Mn and EBITDA of INR 23 Mn in Q1 FY27

HCG delivered Adjusted EBITDA[1] of INR 1,339 Mn in Q1FY27, up ~20% YoY

- Adjusted EBITDA[1] margin **improved to 19.4% in Q1 FY27 from 18.2% in Q1 FY26**, driven by continued improvement in quality of revenue
- Reported EBITDA was INR 1,223 Mn impacted due to start up losses of North Bangalore facility amounting to INR 70 Mn and EPCG related provision of INR 46 Mn

Key Business Developments:

1. **North Bangalore Launched**
   - **Successfully commenced operations** in May 2026 with 56 operational beds, potential to expand bed capacity to 120+ beds
   - **Strong traction** post launch with 550+ New Patient registrations, 300+ admission and **Revenue of INR 67 million in the first quarter**
   - **MR Linac commissioned in July 2026,** making the centre home to one of India's most advanced adaptive radiation therapy platforms and expected to further enhance clinical capabilities and drive patient volume
2. **Total 121 operational beds added, comprising of 56 beds at North Bangalore, 26 beds at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, 7 at Kenya**
3. **Rajkot Upgrade: Enhanced clinical capabilities with the operationalization of a new LINAC, transforming Rajkot into a Comprehensive Cancer Care (CCC) Centre**
4. **Robotics Expansion: Strengthened robotic surgery capabilities with the addition of new surgical robotic systems at Nashik and replacement at Bangalore CoE**

Note: (1) Adjusted EBITDA excludes North Bangalore Loss of INR 70 Mn and EPCG-related provision of INR 45.9 Mn in Q1 FY27 and ESOP of INR 14.5 Mn and M&A-related costs of INR 25.6 Mn in Q1 FY26

Financial Highlights: Q1 FY27

Overall Revenue



Adjusted EBITDA[1]



Volumes (excl. Fertility)[2]



Revenue (excl. Fertility)[2]



Adjusted EBITDA[1] (excl. Fertility)[2]



ARPP (excl. Fertility)[2]



Notes: (1) Adjusted EBITDA excludes North Bangalore Loss of INR 70 Mn and EPCG-related provision of INR 45.9 Mn in Q1 FY27 and ESOP of INR 14.5 Mn and M&A-related costs of INR 25.6 Mn in Q1 FY26
(2) HCG completed the sale of its fertility business on 29th June, 2026

Revenue Mix By Specialty and Payor: Q1 FY27

Specialty Mix Trend



Payor Mix : Increasing Share of Cash & TPA Business in Line with Stated Strategy



Notes:
(1) Modality mix: Excludes fertility business (2) OP + Other services : Includes OPD consultation, diagnostics, pharmacy and IPD related supportive care treatment (3) Payor mix excludes Fertility & International Business

Region-wise Performance Update: South



Revenue Share %



Bed Share[1] %



Q1 FY27

# of Centres	Total Operating Beds	# of LINACs
11	~1,300	16

Q1FY27 Highlights:

- Revenue increased 16% YoY to INR 2,765 million, led by Bangalore CoE and MGCH Vizag and supported by the North Bangalore facility, which commenced operations in May 2026 and contributed INR 67 million in Q1 FY27
- Volume grew 7% YoY. The Bengaluru CoE grew 14%, with growth across modalities

Revenue (INR Mn)



Overall Volumes (# of IP Patients)



Overall ARPP (INR)



(1) Bed share represents Operating beds (Census + Non-Census)

Region-wise Performance Update: West



Revenue Share %



Bed Share[1] %



Q1 FY27

# of Centres	Total Operating Beds	# of LINACs
11	**~1,190+**	**16**

Q1FY27 Highlights:

- Revenue increased 9% YoY to INR 3,010 million. Strong performance in Maharashtra was partly offset by slower growth in Gujarat
- Volume grew 10% YoY, supported by an improved payor mix
- Payor-mix benefits were offset by higher share of medical oncology volumes and focus away from high value, lower margin therapies, leaving ARPP broadly stable

Revenue (INR Mn)



Overall Volumes (# of IP Patients)



Overall ARPP (INR)



(1) Bed share represents Operating beds (Census + Non-Census)

Region-wise Performance Update: East



Revenue Share %



Bed Share[1] %



Q1 FY27

# of Centres	Total Operating Beds	# of LINACs
3	~340+	5

Q1FY27 Highlights:

- Strong revenue growth of 22% YoY, supported by healthy patient volume growth and continued market penetration
- ARPP declined 3% YoY due to case-mix changes and a higher contribution from state-government schemes







(1) Bed share represents Operating beds (Census + Non-Census)

HCG: Growth Plans and Strategic Priorities

Bed Addition: 1,000 beds by FY30, led by 60% brownfield expansion

adding life to years

No. of Operational Beds[1]

31st Mar'26	FY27	FY28 & FY29	FY30	FY30 P
2,734	188 Bed addition	~520 Bed addition	~230 Bed addition	~3,670
	Capex ~INR 1,500 Mn	*Capex ~INR 3,000 Mn*	*Capex ~INR 1,000 Mn*	
	92 Greenfield: North Bangalore; 96 Brownfield beds	~180 Upcoming Greenfield projects; ~340 Brownfield beds	~100 Upcoming Greenfield project; ~130 Brownfield beds	

FY27
- North Bangalore operationalized in Q1'27
- 26 beds added at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, 7 at Kenya
- 18 beds to be operationalized at Bangalore CoE and 13 at Kenya

FY28 & FY29
- Two greenfield projects in pipeline
- Additional beds to be added at Suchirayu (50), Jaipur (30), Nagpur (27), HCC Ahmedabad (23)
- Brownfield capacity addition at Cuttack (75), Vizag (50)

FY30
- One Greenfield project
- ~130 brownfield beds across ~7 existing facilities to be ramped in a phased manner

Greenfield Brownfield

No. of LINACs

31st Mar'26	FY27	FY28 & FY29	FY30	FY30 P
38	**2 Linac** North Bangalore, Kenya	**2 Linac** 2 Greenfield projects	**1 Linac** Greenfield project	~43

Note:
1. Operational beds are Revenue generating beds and non-census
2. Bed Capex excludes maintenance capex

Strategic Priorities To Accelerate Long-Term Value Creation

A – Optimize Existing Network	B – Improve Network Efficiency	C – Invest in Growth	D – Enhance Patient Experience
1. Build best-in-class talent → improve case mix	1. Undertake prudent cost optimization initiatives	1. Brownfield expansion across key hospitals	1. Invest in upgrading existing infrastructure
2. Focused marketing efforts to become provider of choice across payor types	2. Focus on operating leverage to improve margins	2. Strengthen presence in existing markets	2. Maintain leadership in medical technology
3. Scale up international business	3. Develop asset light adjacencies – Day care, Diagnostics etc.	3. Enter identified and attractive markets which fit the expansion framework	3. Leverage digital & tech to improve patient experience

HCG's Leadership	Accelerate Revenue Growth	Margin Expansion	ROCE Improvement
Clinical Excellence Differentiator	Focus on Profitable Growth	Operating leverage & efficiency	Disciplined capital allocation

Q1FY27 Consolidated Profit & Loss

Profit and Loss (INR in Mn.)	Q1FY27	Q1FY26	Y-o-Y	Q4FY26
Revenues from Operations	6,933.9	6,118.0		6,502.9
Income from Govt. Grant	17.1	13.6		20.4
Total Revenue from Operations	**6,951.0**	**6,131.6**	***13.4%***	**6,523.3**
Cost of Goods Sold	1,788.0	1,618.7		1,767.1
Employee Cost	1,045.2	977.7		924.7
Medical Consultancy Charges	1,574.7	1,330.2		1,403.3
Other Expenses	1,320.5	1,127.1		1,177.4
Reported EBITDA	**1,222.6**	**1,077.9**	***13.4%***	**1,250.8**
Reported EBITDA Margin (%)	**17.6%**	**17.6%**	**-**	**19.2%**
North Bangalore losses	70.2	Na	*Na*	Na
One time cost	45.9	25.6		1.5
ESOP's	-	14.5		-
Adjusted EBITDA	**1,338.7**	**1,118.0**	***19.7%***	**1,252.3**
Adjusted EBITDA Margin (%)	**19.4%**	**18.2%**	***+121 bps***	**19.2%**
Depreciation	704.2	579.1		628.1
Other Income	121.3	68.3		130.7
EBIT	**639.7**	**567.1**	***12.8%***	**753.4**
Finance Cost	398.7	454.7		427.0
Extraordinary Items	-	-		319.1
Share in Profit/(loss) in JV and Associates	9.3	6.8		5.2
Profit before Tax	**250.3**	**119.2**	***110%***	**12.5**
Taxes & Non controlling interest	112.6	71.7		9.2
Profit After Tax	**137.7**	**47.5**	***190%***	**21.7**
PAT Margin (%)	**2.0%**	**0.8%**	***+121 bps***	**0.3%**
Adj. Profit After Tax(1)	**137.7**	**47.3**	***190%***	**340.8**
Adj. PAT Margin (%)	**2.0%**	**0.8%**	***+121 bps***	**5.2%**
EPS (On reported PAT)	**0.92**	**0.34**		**0.15**

Note: (1) Q4FY26 Adjusted PAT (post Non controlling interest) is normalized for goodwill impairment of fertility business (INR 319mn)

Q1FY27 Operational Metrics

Key Metrics	South		West		East		Consolidated[1]	
	Q4FY26	Q1FY27	Q4FY26	Q1FY27	Q4FY26	Q1FY27	Q4FY26	Q1FY27
Bed Capacity	1,343	1,483	1,440	1,440	333	359	3,131	3,304
Operational Beds	1,238	1,299	1,163	1,190	318	344	2,734	2,855
Census Beds[2]	942	991	1,066	1,093	310	334	2,333	2,440
In-Patient Volume	31,723	32,915	30,249	31,789	11,095	12,296	74,748	78,914
ARPP (INR)	82,169	84,001	94,710	94,702	63,018	64,983	85,176	85,943

Note:
1.Consolidated is including the International business (Kenya operations) and excluding fertility business
2.Census beds comprises of Revenue generating beds including IPD/Ward beds and Chemo beds

HCG: India’s Leading Oncology Platform

A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment

HCG adding life to years

1. **Largest oncology-focused hospital chain** with a pan-India network
2. **Preferred destination for leading oncologists** to deliver advanced cancer care
3. **Deploying latest medical technology** Enabling doctor to deliver cancer care with precision
4. **Focused approach** and **Tumor Board** enabling effective cancer care
5. **A leading destination for Comprehensive Cancer Care** from early diagnosis and treatment to Survivorship
6. **Marquee leadership team** and experienced management

Underpinned by a personalized patient-centric approach, superior technology, and industry leading medical excellency

Note: (1) HCG in top 3 based on management estimates. (2) Excluding Chennai

1. Largest Pan-India Oncology Focused Hospital Chain



Largest Geographical Reach…

19 /10 Number of Cities and states covered[1]	**26** No. of hospitals[3]
3k+ Capacity beds[3]	**16/19** Leading positions[2]

…With Leading Treatment Infrastructure

38 Number of LINACs[4]	**20** Number of PET CTs
105 Operation theatres[3]	**11** Number of Robotic machine[5]

Note: (1) Excludes Kenya; (2) HCG in top 3 based on management estimates; excludes Chennai; (3) Includes multispecialty; (4) Includes Rajkot and MSR; (5) Includes #1 ortho robotic machine at Rajkot

2. Preferred Platform for Leading Oncology Specialists

adding life to years

Integrated Oncology Ecosystem

Full time and exclusive Oncologist	Integrated Medical, Surgical & Radiation Oncology teams
Organ specific Oncology teams	Precision Medicine with clinical protocols

Preferred destination for leading oncologists to deliver advanced cancer care

Focused Specialty with Scale

Oncology-specific clinical pathways	Strong referral network
Higher case complexity and treatment volumes	Superior clinical outcomes

Specialized network impact > better outcome> more referrals > higher doctor satisfaction

Clinical Excellence and Academics

Access to cutting-edge technologies	High degree of clinical autonomy
Strong research and academics ecosystem	Experienced peer group

Research and collaboration reinforce superior clinical outcomes

450+
Revenue generating Oncologists

350+ robotic surgeries
Total of ~12k Surgeries as of Q1'27

1000+
Paper Published till date

38
LINAC's

88%
Doctor Retention Rate in FY26

30+
New Clinical Trials in FY2026

3. Introducing Latest Medical Technology in Cancer Care

adding life to years

TRACK RECORD OF BEING 1st TO LAUNCH ADVANCED TECHNOLOGY IN INDIA

2026	MR-LINAC[1]
2022	AI- based RIS PACS
2022	Ethos / Adaptive Radiation
2018	Radixact
2016	Tomotherapy - H
2013	Genomics
2012	FFF Technology
2009	Cyberknife, SRS/ SBRT
2006	Cyclotron

Introducing organ-specific working committees – gastrointestinal, head & neck, breast, etc. for better data collection & analysis to improve patient outcome

State-of-the-art Equipment in each modality

DIAGNOSTICS

Total PET CTs : 20

Digital PET

Digital CT Pathology

Automated Breast Volume Scanner

Digital Mammography

Skyra Tesla 3T for MRI

Molecular / Genomics l ab

RADIOTHERAPY

Total LINACs : 38

Cyber Knife

MR-LINAC

True Beam

Versa HD

Radixact

Tomotherapy

MEDICAL/SURGICAL ONCOLOGY

Total Robots: 11

Da Vinci Robot

Versius Robot



Holo Lens

Bone Marrow Transplant Units

Note:(1) In new North Bangalore facility operational from July'26

4. Tumor Board Approach to Deliver Customized Treatment

adding life to years

Spearheaded by Dr. Ajai, who also heads IRC[1] of 30+ oncologists for Investigator Initiated Research Studies

17+ years of nation-wide **Tumor Boards** held weekly

Supplemented by multiple **local tumor boards**

Multi-disciplinary Tumor Board ...

250+
Oncologists participated

36K+
Cases discussed till date

... Takes Inputs From Large Network ...

Decision Making Body	Panelists	Participants
Tumor board Convenor	Leading Oncologists	Treating clinicians
Chairman	Radiologists/ Pathologists	Support Specialities[2]
Special committee	Clinical Experts and academicians	All other clinicians

... Is Patient Focused

- Highly specialized team
- Patient centric
- End-to-end services
- Accuracy and reliability

Case Selection → Preparation → Deliberation → Execution

Sources: Company information
Note: 1 Institutional Research Committee, 2 Clinical Pharmacology, Genomics, Clinical Nutrition and Dietetics, Yoga, Speech & Swallow, Dental etc.

5. A Leading Destination for Comprehensive Cancer Care From Early Diagnosis and Treatment to Survivorship

HCG adding life to years

Diagnostics

Genomics and Molecular diagnostics | **Digital PET** | **Preventive Oncology**

- Physical Examination
- Laboratory Tests
- Home Health Services
- Digital Pathology
- Digital PET
- Preventive Oncology
- Genomics
- CTC[1] detection

Treatment

Medical Oncology and Haemato-Oncology | **Radiation Oncology** | **Surgical Oncology** | **Molecular Imaging and Theranostics**

- Chemotherapy
- Radiation
- Robotic Surgery
- Actinium and Lutetium therapy
- Immunotherapy
- Targeted Drug Therapy
- Psycho-oncology
- Liver Transplant
- Iodine Therapy
- Bone Marrow Transplant
- Pediatric Oncology
- Organ preservation & Reconstructive surgery
- Endocrine Therapy

Post Care

Psychological support | **Preventive Oncology**

- Patient Care
- Home Health Services
- Psychological Support
- Preventive Oncology
- Nutrition
- Rehab
- Genetic Counselling

Note: (1) Circulating Tumor Cells

6. Experienced Board of Directors

Dr. BS Ajai Kumar
Founder and Non-Executive Chairman

Visionary and key driving force of HCG, with an aim to make advanced cancer care accessible

Dr Manish Mattoo
Executive Director and CEO

Seasoned healthcare leader with 20+ years of clinical & business expertise driving healthcare management

Akshay Tanna
Non-Executive Director

Partner at KKR with 20+ years of investing and finance experience. Board member at JB Pharma, BMH, Healthium, Avendus, etc.

Simrun Mehta
Non-Executive Director

Managing Director at KKR, serving on Boards of Vini Cosmetics, Lighthouse Learning, Avendus, BMH etc.

Anjali Ajaikumar Rossi
Non-Executive Director

Social entrepreneur with over 15 years in healthcare; focused on quality and strategy

Geeta Mathur
Non-Executive Independent Director

Experienced finance professional, serving on Boards of Ashok Leyland, Info Edge, JSW One, IIFL group etc.

Rajagopalan Raghavan
Non-Executive Independent Director

30+ years of leadership experience. Currently serving as Chief Human Resource Officer at CoreStack

Pradip Kanakia
Non-Executive Independent Director

36+ years in audit and governance and have held leadership positions in Price Waterhouse, KPMG. On the Board of JM Financial, Britannia Industries, ICRA Limited etc.

Rajiv Maliwal
Non-Executive Independent Director

Founder of Sabre Partners with 30+ years of investment experience. Board member at Wellspring Healthcare, Monepeak Fintech etc.

Bijou Kurien
Non-Executive Independent Director

Consumer industry leader with 40+ years experience across Titan & Reliance Retail. Board member & advisor to multiple companies

HCG Shareholding Pattern and Key Shareholders

adding life to years



Top Institutional Investors as on 30th June 2026

AXIS MUTUAL FUND

pnb MetLife LIFE INSURANCE

TATA mutual fund

TATA AIA LIFE INSURANCE

motilal oswal Mutual Fund

Bandhan Mutual Fund

Nippon india Mutual Fund Wealth sets you free

InCred Asset Management

* All logos are for representation purpose only and copyright belong to the respective owners

Annexure: Definitions

Key Metrics	Definitions
Bed Capacity	Bed Capacity reflects total beds that can be accommodated in the hospitals
Operational / Census Beds	Operational beds comprises of Census and non-census beds
Census Beds	Revenue generating beds including IPD/Ward beds and Chemo beds
Non-Census Beds	Transient Beds including Emergency, triage, pre-op/post op etc
Volume	In-patient volume includes IPD volumes, Chemo cycle and Radiation volume
ARPP (In INR)	Revenue from Operations / In-patient Volume

CIN: L15200KA1998PLC023489

About Us: HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 26 hospitals across India and Kenya, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof.

For updates and specific queries, please visit www.hcgoncology.com or contact:

HealthCare Global Enterprises Limited
investors@hcgoncology.com

Ravi Gothwal
Head Investor Relations
Ravi.gothwal@hcgel.com
Tel: +91 95996 55711

Anoop Poojari / Suraj Digawalekar
CDR India
anoop@cdr-india.com / suraj@cdr-india.com
Tel: +91 98330 90434 / +91 98211 94418

THANK YOU